Tacrolimus Compared With Cyclosporine Microemulsion in Primary Simultaneous Pancreas–Kidney Transplantation: The EURO-SPK 3-Year Results

• Published in: Transplantation proceedings 2005-07, Vol.37 (6), p.2843-2845
• Main Authors: Malaise, J., Saudek, F., Bouc̆ek, P., Adamec, M., Van Ophem, D., Squifflet, J.P.
• Format: Article
• Language: English
• Subjects: Adrenal Cortex Hormones - therapeutic use; Biological and medical sciences; Cyclosporine - administration & dosage; Cyclosporine - therapeutic use; Emulsions; Fundamental and applied biological sciences. Psychology; Fundamental immunology; Graft Survival - drug effects; Humans; Immunosuppressive Agents - therapeutic use; Kidney Transplantation - immunology; Kidney Transplantation - mortality; Medical sciences; Pancreas Transplantation - immunology; Pancreas Transplantation - mortality; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Survival Analysis; Tacrolimus - therapeutic use; Tissue, organ and graft immunology
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2005.05.024

This 3-year study compared tacrolimus versus cyclosporine (CsA) microemulsion (ME) in conjunction with rATG induction, mycophenolate mofetil (MMF) and short-term corticosteroids in primary simultaneous pancreas–kidney (SPK) transplantation. This large, prospective, multicenter study was conducted in 10 European centers and one center in Israel. Of the 205 SPK transplants performed from 1998 to 2000, 103 patients were randomly assigned to tacrolimus and 102 to CsA ME. All patients received concomitant rATG induction therapy, MMF, and short-term corticosteroids. In total, 36.9% patients receiving tacrolimus and 57.8% receiving CsA ME discontinued treatment ( P = .003). Although 3-year patient and kidney graft survival rates were similar in both groups, pancreas survival was superior with tacrolimus (89.2% versus 72.4%; P = .002). Thrombosis resulted in pancreatic allograft loss in 10 patients receiving CsA ME and in 2 treated with tacrolimus ( P = .02). The first episode of biopsy-proven rejection was moderate or severe in 1 of 31 tacrolimus-treated patients and 11 of 39 patients receiving CsA ME ( P = .009). Overall adverse event frequency was similar in both groups, but surgical events were lower in the tacrolimus treated group. Tacrolimus was more effective than CsA-ME to prevent moderate or severe kidney or pancreas rejection after SPK transplantation. It also provided superior pancreatic graft survival and reduced the risk of pancreas thrombosis.